A Positive FIT Nobody Followed Up

The positive FIT is the dominant issue and it is not negotiable.

• A positive FIT in a screening-eligible adult carries a substantial probability of advanced neoplasia - on the order of 5-10% for cancer and 30-40% for advanced adenoma in programmatic data. FIT is a triage test, not a diagnostic test. Its job is to select people for colonoscopy.
• Repeating the FIT is a category error: a subsequent negative FIT does not exclude the lesion that caused the first positive result, and the false reassurance delays diagnosis. There is no guideline that endorses repeat FIT after a positive result.
• The year of delay already occurred. Acknowledge it without blame and move directly to scheduling, but document that the delay was discussed.

The colonoscopy question:

• A normal, complete, adequately prepared screening colonoscopy in an average-risk person resets the clock 10 years - so at 12 years he is already overdue on that pathway.
• The positive FIT overrides the interval logic entirely: he needs a diagnostic colonoscopy now, and the prior normal exam does not lower the urgency.
• If the prior exam was incomplete, poorly prepped, or if polyps were removed, the surveillance interval is different - obtain the actual procedure report rather than accepting the patient's summary.

Family history check: his father's colorectal cancer at 71 is not early-onset (the threshold is under 60), and he is not known to have two affected first-degree relatives. So he remains average risk and does not meet criteria for earlier or more frequent colonoscopy on family history grounds. This is worth documenting so nobody escalates him inappropriately - and worth revisiting if a relative is diagnosed younger or a second first-degree relative is affected.

Action: referral for colonoscopy with clear instructions, a tracking mechanism, and a safety-net contact so the loop closes.

Eligibility check against the 2021 USPSTF criteria (annual low-dose CT):

1. Age 50-80: meets - he is 63.
2. At least 20 pack-years: meets - 1.5 packs/day x 24 years = 36 pack-years.
3. Currently smokes, or quit within the past 15 years: meets - quit 12 years ago.
4. Asymptomatic and willing to undergo curative treatment if found: appears to meet.

Conclusion: he is eligible. One further point that is easy to miss: screening stops at age 80 or 15 years after quitting, whichever comes first. At 12 years since quitting he has roughly 3 years of eligibility remaining, so this is a limited-window decision, not an open-ended annual habit.

Shared decision-making elements to cover and document:

• Benefit: reduced lung cancer mortality with annual low-dose CT in eligible high-risk adults; the absolute benefit is modest per person but real, and it depends on actually completing annual rounds.
• Harms: a substantial rate of false-positive findings requiring repeat imaging or procedures, incidental findings outside the lung (thyroid, coronary calcification, aortic aneurysm), radiation exposure, and overdiagnosis of indolent cancers that would never have caused harm.
• Adherence is part of consent: a one-time scan provides little of the trial-proven benefit.
• Coverage requirement: a counseling-and-shared-decision visit must be documented for coverage; note this explicitly.
• Not a substitute for cessation: he has already quit, so reinforce that and confirm he remains abstinent.
• Symptoms change the pathway: if he develops hemoptysis, unexplained weight loss, or persistent cough, that is diagnostic evaluation, not screening.

Do not conflate with his dyspnea or other issues - screening is for asymptomatic people, and any symptom-driven imaging is ordered on its own merits.

First, correct the risk attribution. The affected relative is a paternal uncle - a second-degree relative - and his father had colorectal, not prostate, cancer. He therefore does not have the strong family history (father or brother affected, or multiple affected relatives) that would justify a targeted or earlier screening discussion. This is a meaningful distinction: the colorectal question and the prostate question do not carry the same weight here.

Second, apply the actual recommendation. For men 55-69, PSA screening is a shared, individualized decision - not a routine order. For men 70 and older it is recommended against. At 63 he falls in the individualized-decision band.

Third, conduct a genuine shared decision conversation:

• The benefit is a small absolute reduction in prostate cancer death - roughly 1 fewer death per 1,000 men screened over about a decade.
• The harms are large and common: false-positive PSA, biopsy complications (infection, bleeding), and overdiagnosis of cancers that would never have caused symptoms - a substantial fraction of screen-detected disease.
• Treatment of screen-detected cancer carries real risk of incontinence and erectile dysfunction.
• If he chooses screening, use PSA without a routine digital rectal exam as the initial test, with a clear plan for what a borderline result would trigger, and set an expectation of roughly every-2-year intervals rather than annual testing by default.

Fourth, be explicit about the contrast with the FIT: the FIT result is an abnormal test that mandates action. The PSA question is a preference-sensitive decision about whether to start. Treating them with the same urgency, or the same casualness, would be a clinical error in both directions.

Documentation: record that the discussion occurred, that he was informed of benefits and harms, and what he chose - regardless of which way he chooses.